Medicare Enrolled
Dr. Alec Goldenberg, MD
Hematology & Oncology · New York, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Goldenberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Goldenberg?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Goldenberg
Dr. Alec Goldenberg is a hematology & oncology specialist in New York, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Goldenberg performed 105,856 Medicare services across 2,681 unique beneficiaries.
Between the years covered by Open Payments, Dr. Goldenberg received a total of $2,579 from 43 pharmaceutical and/or device companies across 117 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Goldenberg is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in NY
$2,579 industry payments
Medicare Practice Summary
Medicare Utilization ↗105,856
Medicare services
Top 6% in NY for hematology & oncology
2,681
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,293 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
52,103 | $0 | $0 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
22,907 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
7,304 | $0 | $0 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
3,621 | $5 | $9 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
3,165 | $5 | $5 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,163 | $8 | $9 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
3,105 | $112 | $155 |
| Injection, granisetron hydrochloride, 100 mcg | 2,888 | $0 | $0 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
1,250 | $19 | $30 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
1,131 | $0 | $1 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
777 | $26 | $46 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 763 | $8 | $10 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
758 | $59 | $91 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
668 | $78 | $110 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
471 | $1 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
373 | $12 | $20 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
335 | $27 | $46 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
303 | $122 | $187 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
301 | $12 | $16 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
211 | $1 | $1 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
115 | $149 | $215 |
| New patient office visit, complex (60-74 min) | 81 | $197 | $264 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
32 | $151 | $200 |
| Deep bone biopsy using needle or trocar A procedure to obtain a tissue sample from deep within the bone using a needle or trocar for examination. |
31 | $358 | $620 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.8% high complexity
86.2% medium
10.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,579
Total received (2018-2024)
Avg $516/year across 5 years
Top 44% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
117
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,480 (96.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$99 (3.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,221
2023
$918
2022
$279
2020
$13
2018
$147
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$121
Celgene Corporation
$110
Lilly USA, LLC
$95
Ipsen Biopharmaceuticals, Inc
$76
Janssen Biotech, Inc.
$75
PFIZER INC.
$71
Acrotech Biopharma Inc.
$67
Tempus AI, Inc
$66
Alexion Pharmaceuticals, Inc.
$51
Takeda Pharmaceuticals U.S.A., Inc.
$41
GlaxoSmithKline, LLC.
$41
Agios Pharmaceuticals, Inc.
$39
Alnylam Pharmaceuticals Inc.
$35
Mirati Therapeutics, Inc.
$30
TAIHO ONCOLOGY, INC.
$28
EMD Serono, Inc.
$26
Kyowa Kirin, Inc.
$25
Kite Pharma, Inc.
$24
Eisai Inc.
$21
ARRAY BIOPHARMA INC
$21
Octapharma USA, Inc.
$21
ABBVIE INC.
$21
Azurity Pharmaceuticals, Inc.
$20
Novartis Pharmaceuticals Corporation
$20
E.R. Squibb & Sons, L.L.C.
$19
Astellas Pharma US Inc
$19
Merck Sharp & Dohme LLC
$19
Gilead Sciences, Inc.
$17
Top 3 companies account for 26.7% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$280
Janssen Biotech, Inc.
$184
Lilly USA, LLC
$170
GENZYME CORPORATION
$138
Acrotech Biopharma Inc.
$121
Kyowa Kirin, Inc.
$107
GlaxoSmithKline, LLC.
$87
ABBVIE INC.
$80
Daiichi Sankyo Inc.
$79
Gilead Sciences, Inc.
$76
Ipsen Biopharmaceuticals, Inc
$76
PFIZER INC.
$71
Tempus AI, Inc
$66
Takeda Pharmaceuticals U.S.A., Inc.
$64
Seagen Inc.
$64
Incyte Corporation
$61
Alexion Pharmaceuticals, Inc.
$51
E.R. Squibb & Sons, L.L.C.
$51
Sobi, Inc
$50
Puma Biotechnology, Inc.
$50
Pharmacyclics LLC, An AbbVie Company
$47
Octapharma USA, Inc.
$43
Kite Pharma, Inc.
$43
Amgen Inc.
$40
Agios Pharmaceuticals, Inc.
$39
Merck Sharp & Dohme LLC
$39
Novartis Pharmaceuticals Corporation
$37
Alnylam Pharmaceuticals Inc.
$35
Mirati Therapeutics, Inc.
$30
TAIHO ONCOLOGY, INC.
$28
EMD Serono, Inc.
$26
Helsinn Therapeutics (U.S.), Inc.
$25
AstraZeneca Pharmaceuticals LP
$25
AVEO Pharmaceuticals, Inc.
$24
CSL Behring
$22
Eisai Inc.
$21
ARRAY BIOPHARMA INC
$21
Azurity Pharmaceuticals, Inc.
$20
Shield Therapeutics Inc
$20
Astellas Pharma US Inc
$19
INSYS Therapeutics Inc
$19
Genentech USA, Inc.
$15
Shire North American Group Inc
$15
Top 3 companies account for 24.6% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · BELEODAQ · DARZALEX · DOPTELET · ENJAYMO · EPKINLY · ERLEADA · Erleada · FARESTON · FOTIVDA · Fabhalta · GIVLAARI · HYQVIA · Hizentra · IBRANCE · IMBRUVICA · INJECTAFER · JAKAFI · JAYPIRCA · KEYTRUDA · KRAZATI · LONSURF · LORBRENA · LUPRON DEPOT · Lenvima · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONCASPAR · OPDIVO · OPDUALAG · Onivyde · PADCEV · PANZYGA · PEMAZYRE · POTELIGEO · PYRUKYND · Padcev · Pomalyst · Poteligeo · REBLOZYL · SARCLISA · SHINGRIX · SUBSYS · TAGRISSO · TECENTRIQ · TRUSELTIQ · TUKYSA · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · XT CDX · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
735
Per 100K population
45.2
County median income
$104,553
Nearest hospital
BELLEVUE HOSPITAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Goldenberg is a mixed practice specialist, with above-average Medicare volume (top 6% in NY), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Goldenberg experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Goldenberg performed 52,103 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Goldenberg receive payments from pharmaceutical companies?
Yes. Dr. Goldenberg received a total of $2,579 from 43 companies across 117 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Goldenberg's costs compare to other hematology & oncology specialists in New York?
Dr. Goldenberg's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Goldenberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in New York
Browse hematology & oncology specialists in New York ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology